Abstract: This invention discloses the use of an E-selectin antagonist and a mobilizer of hematopoietic stem cells or progenitor cells in methods and compositions for treating or preventing immunocompromised conditions resulting from medical treatment. The present invention is particular relevant for prophylaxis and/or treatment of hematopoeitic disorders including neutropenia, agranulocytosis, anemia and thrombocytopenia in individuals receiving or proposed to receive treatments that target rapidly dividing cells or that disrupt the cell cycle or cell division.

Abstract: Enhancing the cellular uptake of a drug or dietary supplement by administering it concurrently with one or more members of the d-tetrandrine family.

Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.

Abstract: The purpose of the invention is to produce an imidafenacin-containing percutaneously absorbed preparation, wherein the drug not only is not allowed to crystallize but also has adequate skin penetration. The imidafenacin-containing percutaneously absorbed preparation comprises isostearic acid and a fatty acid ester, which function as crystallization-preventing agents.

Abstract: Provided is a pharmaceutical composition including an 11-deoxy-prostaglandin compound represented by formula (I): and a fatty acid ester. By mixing the compound of formula (I) and a fatty acid ester, the compound of formula (I) will be stabilized.

Abstract: A lipid particle can include a cationic lipid. Synthesis of the cationic lipid can include a ylide-based reaction, such as a Wittig reaction or sulfur ylide reaction. In some cases, the synthesis can also include a Michael addition or a related addition reaction.

Abstract: The present invention relates to novel tigecycline compositions with improved stability in both solid and solution states and processes for making these compositions. These compositions comprise tigecycline, a suitable carbohydrate, and an acid or buffer.

Abstract: A coating material, containing a mixture of i) a polymer obtained by radical polymerization from a) N,N-diethylaminoethyl methacrylate, and b) at least one radically polymerizable compound, selected from esters of ?,?-ethylenically unsaturated mono- and dicarboxylic acids with C1-C18 alkanols, as component A, ii) one or more antioxidants as component B, iii) one or more plasticizers as component C, and iv) other excipients as components D, wherein the total amount of the mixture of components A-D is 100 wt. %.

Abstract: An occlusive dressing made with an elastomeric gel and one or more active agents is described. The elastomeric gel contains a plasticizing oil phase and a block copolymer agent. Methods of preventing, treating, curing or mitigating an infectious disease and methods of making the dressings are also disclosed.

Abstract: A stable galenic composition of a compound of general formula (I) wherein R1 and R2 both represent independently of each other an alkyl, aryl, arylalkyl group, optionally substituted with one or more linear or branched groups, optionally bearing one or more heteroatoms, comprising said compound of formula I in an amount ranging from 0.01 to 15% by weight based on the total weight of the final composition; at least one anhydrous ester, the main chain and/or optionally the branched chains of which are free from free and/or reactive groups or functions, in an amount ranging from 0.1 to 99.9% by weight based on the total weight of the cosmetically and pharmaceutically acceptable composition; and optionally a cosmetically and pharmaceutically acceptable excipient for completing the 100% of the total weight of the composition.

Abstract: The present invention is based on the surprising discovery that the inclusion of an anionic polymer in the adenovirus formulation enhances long-term stability of the vector composition. An aqueous formulation comprising an adenovirus vector and at least one anionic polymer is provided, together with methods of the preparation of a storage stable adenovirus aqueous formulation.

Abstract: This invention provides for a process of rapidly forming silk fibroin gelation through ultrasonication. Under the appropriate conditions, gelation can be controlled to occur within two hours after the ultrasonication treatment. Biological materials, including viable cells, or therapeutic agents can be encapsulated in the hydrogels formed from the process and be used as delivery vehicles.

Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.

Abstract: A multi-arm polyethylene glycol (I) having different kinds of reactive groups and the uses thereof are disclosed, which is formed by polymerizing ethylene oxide with oligo-pentaerythritol as an initiator, wherein, PEG is same or different and is —(CH2CH2O)m-, the average value of m is an integer of 2-250; l is an integer of 1 or more. The method for producing the multi-arm polyethylene glycol having different kinds of reactive groups, the multi-arm polyethylene glycol active derivatives comprising linking groups X attached to PEG and terminal reactive groups F attached to X, the gels formed by the multi-arm polyethylene glycol active derivatives, the drug conjugates formed by the multi-arm polyethylene glycol active derivatives and drug molecules, and the uses thereof in preparing drugs are also disclosed.

Abstract: The present invention is directed to a method for producing a biomolecule conjugate where the method is integrated into a single unit operation.

Abstract: This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable.

Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

Abstract: Auristatin compounds and conjugates thereof are provided herein. The conjugate comprises a protein based recognition-molecule (PBRM) and a polymeric carrier substituted with one or more -LD-D, the protein based recognition-molecule being connected to the polymeric carrier by LP. Each occurrence of D is independently an Auristatin compound. LD and LP are linkers connecting the therapeutic agent and PBRM to the polymeric carrier respectively. Also disclosed are polymeric scaffolds useful for conjugating with a PBRM to form a polymer-drug-PBRM conjugate described herein, compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions.

Abstract: The invention relates to the field of pharmaceutics and medicine and concerns a nano-diamond conjugate with glycine for delivering glycine into an organism, the conjugate comprising nano-diamond particles modified by glycine, with a particle size of 2-10 nm, and containing up to 21% by mass of glycine which is included in the composition of the superficial shell of said particles with a thickness of up to 1 nm, and to a method for producing said conjugate.

Abstract: The present invention discloses a process for preparing a compound having the formula Including Reacting a compound of the formula 1: with a compound of the formula: in the presence of a polar solvent and trifluoroacetic acid to provide a compound of the formula: or a racemic mixture thereof; and further reacting the compound of the formula: or a racemic mixture thereof; with sodium hydroxide and a compound of the formula: wherein R1 and R2 are as defined above.

Abstract: Disclosed is a disinfecting station for at least one portable electronic device. An enclosure is adapted to receive the at least one portable electronic device therein through an openable side that includes a selectively closable door. Each electronic device is exposed to a disinfecting wavelength of light, such as UV light, to disinfect the surface of the device. The enclosure can include supports that minimally contact each device so that the device will be substantially exposed to the UV light. A control circuit can monitor the exposure time and level, and is programmable to activate the UV light based on pre-set criteria. The enclosures may be stacked and provide power and network connectivity to each device while docked therein.

Abstract: The method and the device according to the invention are used to sterilize preforms (1) made of a thermoplastic material that are intended for producing blow-molded containers. During the sterilization, a sterilizing agent is introduced into the area of the preform (1). The sterilizing agent is discharged at least partially from at least one nozzle (44) in the direction of the preform (1). An average direction (45) of the escape of the sterilizing agent from the nozzle (44) is provided with an angle of inclination (46) from a longitudinal axis (47) of the preform (1).

Abstract: The present invention provides a mobile power pack with fragrance feature is disclosed. An outer surface of the housing is formed with an accommodating space, and a power module is installed in the housing. A heating element is disposed in the housing and corresponding to the accommodating space, and the heating element is electrically connected with the power module. A fragrant shim is disposed in the accommodating space, and the fragrant shim is heated by the heating element for producing aromas.

Abstract: In the prior art, there has not been provided a fiber that can quickly and persistently deodorize and absorb the smell and the damp feeling due to body fluid generated from the body. The present invention provides a fiber having such property, and specifically provides a moisture-absorbing and deodorizing fiber, characterized in that, a basic polymer is ionically-bonded in an amount of 0.2 to 4 mmol/g as an amount of amino group onto the surface of a moisture-absorbing fiber having a crosslinked structure and also having 3 to 8 mmol/g of carboxyl group.

Abstract: Various embodiments of a device are shown and disclosed for closing a vascular access puncture site following percutaneous diagnostic or therapeutic interventional procedures. The vascular closure device is configured to safely and accurately deploy a sealing material that undergoes a phase change when deployed inside the tissue tract. The sealing material may be a solid at room temperature and a liquid or gel at body temperature. Also, the sealing material may change from a liquid or gel to a cubic phase when it comes into contact with bodily fluids.

Abstract: The present invention relates to a polyurea system encompassing as component A) isocyanate-functional prepolymers obtainable by reaction of aliphatic isocyanates A1) with polyols A2), which can in particular have a number average molecular weight of ?400 g/mol and an average OH functionality of 2 to 6, as component B) amino-functional compounds of general formula (I) in which X is an organic residue comprising a tertiary amino function, having no Zerewitinoff active hydrogen, R1 is a CH2—COOR3 residue, in which R3 is an organic residue having no Zerewitinoff active hydrogen, a linear or branched C1 to C4 alkyl residue, a cyclopentyl or cyclohexyl residue or H, R2 is an organic residue having no Zerewitinoff active hydrogen, n is an integer ?2 or ?3, in particular for closing, binding, bonding or covering cell tissue, and to a metering system for the polyurea system according to the invention.

Abstract: Disclosed are a biodegradable, biocompatible hydrogel that can be used for sealants of suppressing the leakage of blood or air during surgical operation, tissue adhesives, anti-adhesive agents and drug delivery carriers, and a method for producing the same.

Abstract: The present invention relates to a medical device comprising both pyrolytic carbon and an NO generator, methods of making same, and methods of using same.

Abstract: Implantable medical devices having a metallic surface coated with a bioabsorbable primer polymer layer under a bioabsorbable drug polymer layer. Thus, in addition to the degradation of the drug polymer layer, there is degradation of the primer layer. The underlying metallic framework may or may not degrade depending on whether bioabsorbable or biostable metals are chosen.

Abstract: The invention relates to a method for the surface treatment of a biologically inert titanium implant to be placed in contact with a bone of the human body, which involves allowing body fluids, such as the inorganic portion of human blood plasma, to naturally deposit, onto the titanium implant, a calcium phosphate film having the formula Ca5(PO4)3(OH), in the form of hydroxyapatite, with a view to rendering the biologically inert titanium biologically active so as to enable the bone to chemically bond to the implant, thus promoting osseointegration, the method including an operation that involves submerging the titanium in a sodium hydroxide (NaOH) solution, wherein said submersion causes the formation of a film of hydrated titanium oxides (HTiO3—) on the titanium, which in turn causes hydroxyl groups (TiOH) to appear, thus enabling the deposition of said calcium phosphate film.

Abstract: An apparatus including a hollow body, an inlet fluidly coupled to the hollow body, a piston slidably engaged within the hollow body, and a filter arranged within the hollow body between the inlet and piston. The piston and hollow body cooperatively generate a negative pressure, relative to ambient, within the hollow body during piston translation from a first position, proximal the inlet, to a second position, distal the inlet, to draw a fluid, such as blood, through the filter into the hollow body. The piston and hollow body cooperatively generate a positive pressure, relative to ambient, within the hollow body during piston translation from the second position to the first position to egress the filtered fluid from the hollow body.

Abstract: Adjustable covers, systems, and methods are presented that include an adjustable cover that may be adjusted to an appropriate size by hand without requiring cutting tools and without substantial leaks. In one instance, the adjustable covering includes a drape member with a plurality of non-leaking tear paths. Each non-leaking tear path includes a weakened path of the drape member that may be torn. The adjustable covering may further include a first plurality of tear starters formed on a first initiation edge of the drape member. Each tear starter of the first plurality of tear starters is aligned with one of the plurality of tear paths. Each of the first plurality of tear starters is adapted to facilitate the initiation of a tear along a tear path. The grains of the drape member, a backing layer, and support layer may also be in the same direction. Other adjustable covers, systems, and methods are presented.

Abstract: Devices for concentrating fluids that comprise discrete or particulate material dispersed in a liquid medium, such as whole blood, by removal of a proportion of the liquid medium, and a method of producing blood cell concentrates from whole blood using reduced pressure. The devices comprise an outer bag formed of an impermeable material and an inner bag formed of a permeable material, the inner bag containing an absorbent material or being adapted for connection to a source of reduced pressure.

Abstract: The present invention generally relates to systems and methods for the regeneration of spent dialysis solutions. The present invention further relates to systems and methods for continuously regenerating spent dialysis solution during dialysis. The present invention further relates to systems and methods for conducting dialysis that further include using chemical and physical separators in conjunction with ion exchange cartridges and/or adsorption cartridges.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: A container (10) comprising a plurality of compartments (A, B, C) separated by compartment dividers (6), and an inlet connector (3) for receiving a liquid via a connection tube (2). The compartment dividers rupture when a sufficient pressure is applied by a liquid or gas introduced into the container (10) through the inlet connector (3). Some of the compartments comprise powder, which dissolves at the introduction of liquid into the container. A system, process and use in the field of dialysis are also disclosed.

Abstract: A circulation pump and an electrochemical ozone generator are integrated into the permeate return line of an RO system, and the permeate return line is connected in flow direction behind the circulation pump and the ozone generator by a recirculation line to the permeate supply line, which can form a closed circuit where the ozonized permeate circulates until all organic contaminants have been killed or decomposed by the ozone in that part of the line system. Valves are integrated, respectively, into the recirculation line and the permeate return line downstream of the branch of the recirculation line. During normal operation of the RO system, the recirculation line valve is connected for feeding connected dialysis devices while the permeate return line valve is open, so excessive permeate that was not taken by the dialysis devices can flow into the supply tank. Alternatively, the permeate can be discharged into an outlet.

Abstract: Disclosed is a fluid dispensing device that includes at least one reservoir to hold the therapeutic fluid, at least one other unit requiring communication with ambient air, at least partly, to operate, and at least one housing defining an interior to retain the at least one reservoir and the at least one other unit. The at least one housing has at least one vent port formed on one or more of its walls. The at least one vent port is adapted to direct or communicate air to maintain pressure equilibrium between the air pressure in the interior of the at least one housing and the ambient air pressure outside the at least one housing, and provide communication with the ambient air to the at least one other unit requiring air to enable operation of the at least one other unit.

Abstract: An intravascular catheter for peri-vascular and/or peri-urethral tissue ablation includes multiple needles advanced through supported guide tubes which expand around a central axis to engage the interior surface of the wall of the renal artery or other vessel of a human body allowing the injection an ablative fluid for ablating tissue, and/or nerve fibers in the outer layer or deep to the outer layer of the vessel, or in prostatic tissue. The system may also limit and/or adjust the depth of penetration of the ablative fluid into and beyond the tissue of the vessel wall. The catheter may also include structures which provide radial and/or lateral support to the guide tubes so that the guide tubes expand uniformly and maintain their position against the interior surface of the vessel wall as the sharpened injection needles are advanced to penetrate into the vessel wall.

Abstract: The application relates to a drip chamber for an infusion device, to an infusion device with a drip chamber, and to an arrangement composed of an infusion container and of such an infusion device. The drip chamber has a securing part for securing the drip chamber releasably to the infusion container. The securing part of the drip chamber has securing elements which are arranged along the circumference of a circle and which, on the inner sides facing each other, have grooves extending along the circumference of a circle. The securing elements can be spread from a position in which they engage firmly around the connector part of the infusion container to a position in which they release the connector part of the infusion device. The securing elements secure the piercing spike of the drip chamber against slipping out of the piercing part of the connector part of the infusion container.

Abstract: Some embodiments of a wearable infusion pump system can include a pump device having a drive system to dispense a medicine to a user, an activity sensor that detects a possible change in an activity level of the user, and a controller to activate the drive system to dispense the medicine to the user. The controller device can query the user to indicate whether a detected activity level of the user represents an actual change in the activity level of the user. The controller device can alter the medicine dispensing schedule based on the user indicated changes in activity level.

Abstract: Structures and protocols are presented for configuring an unmanned aerial device to participate in the performance of tasks, for using data resulting from such a configuration or performance, or for facilitating other interactions with such devices.

Abstract: An assembly for a drug delivery device (1), comprises a housing (2), a dose member (22), a guide track (42) and a spring member (26). The dose member (22) is adapted to be rotated in a dose setting direction with respect to the housing (2) for setting a dose of a drug (5) and to be rotated in a dose delivery direction with respect to the housing (2) for delivering the set dose. The dose member (22) comprises a guide feature (46). The guide track (42) is configured to mechanically cooperate with the guide feature (46). The guide track (42) comprises a first section (43A) and a second section (43B) which are connected to each other via a connection region (55). The first section (43A) defines an angular start position (54) for the guide feature (46) and the second section (43B) defines an axial stop position (56) for the guide feature (46).

Abstract: A replaceable needle assembly is provided for a retractable syringe comprising a barrel and a plunger, whereby the retractable needle can be replaced by a user without affecting the retraction mechanism. A mounting member is removably mountable to the barrel by way of a screw-thread connection and a needle mount is removably coupled to the mounting member. A needle is mounted to the needle mount. The barrel comprises a needle mount retainer that comprises a plurality of fingers that engage the retractable needle mount to prevent inadvertent retraction. The plunger comprises a collapsible seal which maximizes the efficiency of fluid delivery prior to the plunger engaging the retractable needle mount for retraction. An initially compressed spring decompresses to drive retraction of the plunger and the engaged needle mount. A lock formed between the plunger and barrel prevents further use of the plunger after retraction.

Abstract: A needle assembly has distal and proximal ends. The needle assembly comprises a body element having distal and proximal ends, an attachment means configured to be attached to a medication delivery device, a button element which is movable from a first position to a second position, and a needle configured to move to the distal direction, when the button element is moved from the first position to the second position.

Abstract: In an exemplary embodiment, a breath actuated inhaler (BAI) actuator may include a loading element capable of being loaded with an actuation force and a breath actuated trigger mechanism arranged to counteract the actuation force of the loading element and to fire the actuator by releasing the actuation force of the loading element in response to an inhalation breath. An actuation locking device may be moveable between a locked position wherein it relieves the actuation force from the trigger mechanism setting the trigger mechanism in a neutral position, and an armed position wherein the trigger mechanism is set in an armed position.

Abstract: A process and a device for oxygen regulation of a patient having at least two SPO2 monitors and a control for automatic recognition of which measurements are more reliable. The measurement from one or more of the two SPO2 is used to control the oxygen concentration delivered to a patient based on a comparison of the measurements from the at least two SPO2 monitors.

Abstract: Systems and methods for estimating a leak flow in a breathing assistance system including a ventilation device connected to a patient are provided. Data of a flow waveform indicating the flow of gas between the ventilation device and the patient is accessed. A specific portion of the flow waveform is identified, and a linear regression of the identified portion of the flow waveform is performed to determine an estimated leak flow in the breathing assistance system.

Abstract: A nasal or full-face mask frame includes a main body and a vent assembly provided to the main body. The vent assembly includes a plurality of holes arranged in at least one column. The holes are positioned on a relatively flat and/or non-recessed portion of the main body.

Abstract: The devices and methods described herein relate to improved structures for removing obstructions from body lumens. Such devices have applicability in through-out the body, including clearing of blockages within the vasculature, by recanalizing or removing the obstruction within the body lumen.